NASDAQ · ACAD

Acadia Pharmaceuticals Inc.

$24.84 +$0.01 (+0.04%) 1D After hours
Charting by TradingView

Key Metrics

$4.25B
Market cap
11.32×
P/E · TTM
$1.10B
Revenue · TTM
$375.65M
Net income
EPS · TTM $2.24
Dividend yield —
Free cash flow —
Beta · 1Y 0.96
EBITDA · TTM $116.02M
Gross margin —

Snapshot

Market cap$4.25B
Enterprise value—
Shares outstanding171.2M
52-wk range$19.69 – $28.35
Avg volume · 20D1.8M
Net cash —
Book value / share$7.44
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Acadia Pharmaceuticals Inc.
IPO dateMay 27, 2004
Employees798

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E11.32
P/S3.88
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №$19.37

Profitability

Gross —
Operating 10.5%
Net 34.3%
FCF —
ROE / ROIC 37.9% · 94.7%

Financial Health

Current ratio3.59
Quick ratio3.22
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital$790.49M

Cash Flow · TTM

Operating CF $123.49M
Capex —
Free cash flow —
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

7.1
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$19.37 vs $24.84
Trades 1.3× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings